1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Diaceutics PLC

Diaceutics PLC

DXRX.L
Diaceutics PLCGB flagLondon Stock Exchange
144.00
GBp
-9.00
- -
121.87MMarket Cap
Diaceutics PLC
DXRX.L
(London Stock Exchange)

Recent

price

144.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.07
0.11
0.23
0.21
0.16
0.17
0.23
0.28
- -
0.45
Revenue per Share
0.01
0.01
0.01
0.01
- -
0.01
0.01
-0.02
- -
- -
Basic EPS, GAAP
0.01
0.02
-0.05
-0.06
-0.08
-0.06
- -
-0.04
- -
-0.06
Free Cash Flow per Basic Share
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.01
0.02
0.05
0.04
0.04
0.05
0.07
0.05
- -
0.49
Book Value per Share
0.01
0.02
0.03
0.26
0.4
0.33
0.32
0.3
- -
0.29
Tangible Book Value per Share
70
70
45
64
78
84
84
84
- -
85
Basic Weighted Avg Shares
5
7
10
13
13
14
20
24
32
38
Sales/Revenue/Turnover
19.23
12.23
13.55
15.53
-2.13
3.94
2.95
-12.73
-7.63
0.11
Operating Margin (%)
- -
- -
- -
- -
1
2
3
5
5
6
Depreciation Expense
1
1
1
- -
- -
1
1
-2
-2
- -
Net Income, GAAP
4.82
15.5
27.92
19.92
- -
- -
- -
- -
- -
67.88
Effective Tax Rate (%)
16.28
9
6.1
2.96
2.07
4.02
3.71
-7.37
-5.3
0.25
Profit Margin (%)
2
3
3
16
31
27
27
24
22
21
Working Capital
1
2
1
- -
- -
1
1
1
1
1
LT Debt
1
2
3
20
40
41
43
41
40
40
Total Equity
- -
23.26
19.33
12.45
- -
- -
- -
- -
- -
0.03
Return on Invested Capital (%)
- -
26.37
17.74
12.99
- -
- -
- -
- -
- -
0.27
Return on Capital (%)
- -
60.02
33.76
15.86
8.57
14.74
14.83
-35.91
-7.57
0.23
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
0.17%
1.56%
Free Cash Flow
- -
-348.93%
32.35%
Net Income, GAAP
- -
-61.39%
-105.7%
Sales/Revenue/Turnover
- -
25.29%
19.53%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
24
2024
- -
- -
- -
- -
32
2025
- -
- -
- -
- -
38

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.02
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
ScreenPro Security Inc. (SCRN.CN)
Integral Diagnostics Limited (IDX.AX)
DIVA Laboratories, Ltd. (4153.TWO)
bioMérieux S.A. (BIM.PA)
Fleury S.A. (FLRY3.SA)
Rennova Health, Inc. (RNVA)
Business
Diaceutics PLC (DXRX.L) provides pharmaceutical and biotech companies with end-to-end data analytics, implementation, and advisory services for precision medicine diagnostics through its DXRX platform, the world's first diagnostic commercialization platform integrating real-world testing data from a global network of over 52,000 laboratories across 53 countries; core offerings include Insight Solutions such as Signal for actionable physician testing alerts, Testing Rate Tracker for biomarker adoption trends, Lab Segmentation for global lab insights on test volumes and capabilities, and Physician Segmentation for US physician-lab relationships; Engagement Solutions comprising Lab Engage with DXRX Lab Talks and Alerts for targeted lab education, and Physician Engage for timely physician notifications; Advisory Services encompassing Strategy and Planning for commercialization playbooks, Insights for testing barriers, Market Access for reimbursement tactics, Education and Content for custom workshops, Impact Assessment for risk mitigation, and Consulting for ad-hoc expertise; plus Scientific Services like Ring Studies for assay concordance, Lab Report Optimization, Pharma Lab Induction, Lab Training, and EQA Support to enhance test availability and quality. The company serves 39 to 43 global pharmaceutical firms including 17 of the top 20, targeting oncology and other precision therapies with 481 million de-identified patient records and weekly testing event data; operations span key markets in the US, UK, Ireland, and Singapore from its headquarters in Belfast, Northern Ireland, where it was founded in 2005. Recent developments feature the 2024 launch of its integrated PMx commercialization partner agreement, with the first contract signed in March 2025 with Partner Therapeutics valued up to £13 million through 2028 and strong uptake tracking Bizengri following FDA approval in December 2024; a new enterprise-wide agreement in H1 2025 brings the total to eight such deals representing £10.1 million in annual recurring revenue; expansion of US presence with a New Jersey headquarters, sales team growth to 29 members, and AI-driven platform upgrades for multi-modal data insights; alongside H1 2025 revenue growth of 22% on constant currency to £14.6 million, ARR up 16% to £16.4 million across 74 therapeutic brands, and an order book of £31.7 million including £9 million for H2 delivery.